KRAS and neoplasm: In a recent study including 55 patients with GC tested by NGS, Kato et al. showed that 31 had concordant mutations between tumor tissue and ctDNA with levels ranged from 61.3% (for TP53 mutation) to 87.1% (for KRAS mutation) [61].